SignaBlok Receives Orphan Drug Designation from FDA for TREM-1 inhibitor for the Treatment of Retinopathy of Prematurity
FDA grants Orphan Drug Designation to SignaBlok's first-in-class, new mechanism-based TREM-1 peptide inhibitor to treat retinopathy of prematurity SHREWSBURY, MA, UNITED STATES, March 26, 2026 /EINPresswire.com/ -- SignaBlok, Inc., a …